Education
About Us
Working with TipRanks
Follow Us
Orexo AB (SE:ORX)
:ORX
Earnings Data
Report Date
Feb 05, 2026Before Open (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.3Last Year’s EPS
-3.37Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant R&D progress and strategic developments, such as the BARDA partnership for OX390 and positive growth in the U.S. commercial segment. However, financial challenges remain, including negative EBITDA, revenue declines in the U.S. commercial business, and market uncertainties for OX640. Despite these challenges, strategic initiatives and partnerships indicate potential for future growth.Company Guidance
Significant R&D Progress
Great progress in Orexo's pipeline, particularly with the GLP-1 agonist project OX472 showing promising in vivo data. Also, received BARDA funding for the OX390 project, potentially worth up to $51 million.
Positive Movement in U.S. Commercial Segment
Buprenorphine and naloxone market growth in the U.S. increased by 4% year-over-year, with a slight increase of 1% over the last quarter. The commercial segment is now surpassing Medicaid as the largest segment.
BARDA Partnership for OX390
BARDA funding secured for OX390, initially worth $8 million and potentially up to $51 million, to develop a nasal rescue medication for fentanyl and xylazine overdoses.
Strong U.S. Commercial EBIT
U.S. business EBIT was SEK 38 million for the quarter, up from SEK 25 million year-over-year, with an EBIT margin improvement from 19% to 34%.
SE:ORX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
SE:ORX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 23, 2025 | kr37.50 | kr29.95 | -20.13% |
Jul 16, 2025 | kr20.25 | kr19.00 | -6.17% |
May 06, 2025 | kr14.50 | kr15.00 | +3.45% |
Feb 06, 2025 | kr18.70 | kr19.30 | +3.21% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Orexo AB (SE:ORX) report earnings?
Orexo AB (SE:ORX) is schdueled to report earning on Feb 05, 2026, Before Open (Confirmed).
What is Orexo AB (SE:ORX) earnings time?
Orexo AB (SE:ORX) earnings time is at Feb 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Orexo AB stock?
The P/E ratio of Orexo AB is N/A.
What is SE:ORX EPS forecast?
SE:ORX EPS forecast for the fiscal quarter 2025 (Q4) is -0.3.